The Institut participates in a new clinical trial for exudative AMD with a state-of-the-art drug
AMD is one of the main diseases under research in the field of ophthalmology. At global level, the principal international corporations and benchmark ophthalmological centres are involved in the mission of improving the current treatments for exudative AMD, advancing in prevention and in the techniques for the approach and discovery of treatment for atrophic AMD. The Institut de la Màcula, from the perspective of clinical research, and the Barcelona Macula Foundation, from basic research, form part of this group, which aims to reverse these vision pathologies that were developing inexorably until recently.
In April, the Institut de la Màcula commenced a new clinical trial with a new state-of-the-art long-lasting drug indicated for age-related macular degeneration (AMD) in its exudative type. This is a phase III trial that involves treatment with dual molecular therapeutic action, that is, it blocks the two proteins that act as motors of the development of this disease, while entailing greater efficacy and longer duration. The main aim is to increase the intervals between treatments.
"In the fight against a disease like exudative AMD, we have to be capable not only of acting early but also of continuing to treat the disease for a long time. Having a new drug that maintains or improves the benefits but with a more lasting effect, will positively affect the quality of life of patients in the long term", says Jordi Monés, the Director of the Institut de la Màcula.
The trial, which will last two years, is now in the process of selecting candidates. The trials only accept a limited number of patients and are subject to rigorous inclusion criteria. Those considered would be people of over 50 years old with exudative AMD who have not received treatment for the disease and whose visual acuity is between 20/32 and 20/320.
Participating in this clinical trial gives AMD sufferers the opportunity to access, free of charge, an innovative treatment, with personalised, cutting-edge care by expert ophthalmologists. It is also the sole access route to a new drug that is not yet available to the general public but that has already demonstrated very good results in patients in a previous Phase II clinical trial.